Ground Truth Labs

Ground Truth Labs

AI biomarker quantification for digital pathology

Overview

Ground Truth Labs provides AI-powered biomarker quantification from digital pathology. It analyzes routine histopathology slides to quantify spatial biomarkers, serving pharmaceutical companies, CROs, and healthcare providers. Its platform requires no special staining or obscure data, enabling seamless integration into existing workflows. The company offers its AI-driven biomarker quantification as a service through subscriptions, service contracts, and partnerships. Compared with competitors, it emphasizes deriving actionable, spatial biomarker insights from standard slides and optimizing current data workflows rather than building separate data requirements. The goal is to improve cancer patient outcomes by delivering insights that inform drug development, clinical trial decisions, and clinical diagnosis.

Significant Headcount Growth

About Ground Truth Labs

Simplify's Rating
Why Ground Truth Labs is rated
C-
Rated C on Competitive Edge
Rated C on Growth Potential
Rated D+ on Differentiation

Industries

Data & Analytics

Enterprise Software

AI & Machine Learning

Healthcare

Company Size

11-50

Company Stage

Seed

Total Funding

$4.3M

Headquarters

London, United Kingdom

Founded

2019

Get referred to Ground Truth Labs

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • EHA 2026 presentation with Incyte validates GTL’s biomarkers in a real longitudinal cohort.
  • Oxford Science Enterprises updated GTL’s page in August 2026, signaling active institutional support.
  • GTL’s slide-level quantification fits pharma trial workflows, enabling faster biomarker adoption across hematology.

What critics are saying

  • GTL remained pre-seed/seed in August 2026, signaling limited commercial scale and runway.
  • PathAI, Tempus, and Roche dominate digital pathology, squeezing GTL on validation and distribution.
  • If Incyte and Oxford collaborations stall, GTL loses its only clear market-facing proof point.

What makes Ground Truth Labs unique

  • Oxford Science Enterprises backs GTL; Oxford histopathology expertise shapes its bone-marrow platform.
  • GTL quantifies fibrosis, megakaryocytes, blasts, and plasma cells from routine H&E slides.
  • EHA 2026 data with Incyte showed continuous biomarkers for myeloproliferative neoplasm trials.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$4.3M

Above

Industry Average

Funded Over

1 Rounds

Seed funding is usually the first official round after pre-seed, when a startup has a prototype or concept. It’s typically used to develop the product, test the market, and start building the team. Investors here are often angel investors or early-stage venture capitalists.
Seed Funding Comparison
Above Average

Industry standards

$3.3M
$2M
Netflix
$2.3M
Instacart
$3M
Robinhood
$4.3M
Ground Truth Labs

Benefits

Remote Work Options

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

9%
PR Newswire
Jan 28th, 2026
Tauth Labs certified to issue C2PA content authentication credentials backed by Adobe, Google and OpenAI

Tauth Labs has been certified by the Coalition for Content Provenance and Authenticity (C2PA) as a Certificate Authority for issuing content authentication credentials. The certification allows the company to provide credentials recognised by major platforms including Adobe, Google, OpenAI and LinkedIn. The New York-based company's TauthID solution uses user verification, watermarks and content credentials to authenticate digital content, with optional blockchain logging. Tauth Labs focuses on serving clients in communications, financial services and local government sectors. The company's tools integrate into content management systems and offer features including branded authentication credentials, browser plugins and fake detection capabilities. C2PA's technical standards help verify digital content authenticity and track changes made to it, addressing concerns about AI-generated misinformation.

Ground Truth Labs
Jun 29th, 2023
GTL | Blog - GTL raises $4.3M to launch commercially with AI biomarkers

Quantitative, fast, and novel AI biomarkers for tissue analysis - with results in the context of validated clinical data.

Recently Posted Jobs

Sign up to get curated job recommendations

Ground Truth Labs is Hiring for 1 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →